Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia AB has withdrawn its proposal for a reverse share split and canceled the Extraordinary General Meeting scheduled for 22 January 2026 after discussions with major shareholders indicated the measure was unlikely to gain the required two‑thirds majority. The board’s decision suggests limited shareholder support for the capital structure change, potentially signaling investor caution over the company’s strategic direction and leaving its current share structure unchanged for the time being.
The most recent analyst rating on (SE:IMMNOV) stock is a Hold with a SEK0.20 price target. To see the full list of analyst forecasts on Immunovia AB stock, see the SE:IMMNOV Stock Forecast page.
More about Immunovia AB
Immunovia AB is a Swedish diagnostic company focused on improving survival rates for pancreatic cancer patients through early detection. The company develops and commercializes simple blood-based tests that identify proteins and antibodies indicating pancreatic cancer, targeting high‑risk individuals, particularly in the U.S. market, where it estimates about 1.8 million people could benefit from annual surveillance testing. Immunovia collaborates with healthcare providers, experts and patient advocacy groups, and its shares are listed on Nasdaq Stockholm.
Average Trading Volume: 6,487,171
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK135.5M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.